Cardiovascular Complications in Cancer Therapy
Published on 1. February 2019
Book
Paperback/Softback
XIII, 224 pages
978-3-030-06653-6 (ISBN)
Description
This proposed text is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about vascular damage potentially induced by antineoplastic drugs. Thanks to more and more effective antineoplastic treatments the survival of cancer patients is enormously increasing, but at the same time it is increasing the burden of related cardiovascular complications that affect morbidity and mortality. On this basis a new branch of cardiology has been developed, that is Cardio-Oncology. The aim is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular damage. An increasing attention has been given to cardiac damage, while, until today, vascular complications have been poorly evaluated. The aim of this book is to focus on vascular complications related to cancer treatment, to guide the clinician at facing,during his every day practice, cardiovascular toxicity in cancer and hematologic patients. The proposed sections of the book have been structured to review the molecular mechanisms underlying vascular damage induced by new and old treatments, to describe the various manifestations of vascular disease that may range from artery to venous disease (including coronary artery disease, peripheral arterial disease, venous thromboembolism and pulmonary hypertension), and to provide advice to monitor patients undergoing onco-hematologic treatments in order to prevent and eventually manage vascular damage.This book will address resident and fellow physicians, medical oncologists, cardiologists, general practitioners and all those who take care of these patients.All invited authors will be recognized experts in their field, and leading international researchers on these topics. The editor has worked with these expert colleagues on a variety of other projects.The authors will provide their manuscript according to current literature and clinical research studies. The book does not seek to duplicate or replace other current resources. Rather, it will create a comprehensive yet concise resource on this emerging topic that is not adequately covered by any current literature.
More details
Series
Edition
Softcover Reprint of the Original 1st 2019 ed.
Language
English
Place of publication
Cham
Switzerland
Publishing group
Springer International Publishing
Target group
Professional and scholarly
Illustrations
3 s/w Abbildungen, 38 farbige Abbildungen
XIII, 224 p. 41 illus., 38 illus. in color.
Dimensions
Height: 254 mm
Width: 178 mm
Thickness: 13 mm
Weight
521 gr
ISBN-13
978-3-030-06653-6 (9783030066536)
DOI
10.1007/978-3-319-93402-0
Schweitzer Classification
Other editions
Additional editions
Antonio Russo | Giuseppina Novo | Patrizio Lancellotti
Cardiovascular Complications in Cancer Therapy
Book
10/2018
Humana
€106.99
Shipment within 10-15 days
Persons
Antonio Russo, MD, PhD
Full Professor of Medical Oncology
Department of Surgical, Oncological and Oral Sciences (Di.Chir.On.S.)
University of Palermo, Italy
Director of Medical Oncology Section, University Hospital P. Giaccone
Palermo, Italy
Giuseppina Novo, MD, PhD
Associate Professor of Cardiology
Biomedic Department of Internal Medicine and Specialities (DIBIMIS) University of Palermo, Italy
Division of Cardiology, University Hospital P. Giaccone
Palermo, Italy
Patrizio Lancellotti, MD, PhD
University of Liège Hospital, GIGA Cardiovascular Sciences
Department of Cardiology
CHU Sart Tilman, Liège, Belgium
Gruppo Villa Maria Care and Research, Anthea Hospital
Bari, Italy
Antonio Giordano, MD PhD
Director, Sbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology
College of Science and Technology
Temple University
PA 19122
USA
Fausto J. Pinto, MD, PhD, FESC, FACC, FSCAI, FASE
Professor, University Hospital Santa Maria, CHLN
University of Lisbon, Portugal
Dept. of Cardiology
Av Prof Egas Moniz
Lisboa 1649-028 Portugal
Full Professor of Medical Oncology
Department of Surgical, Oncological and Oral Sciences (Di.Chir.On.S.)
University of Palermo, Italy
Director of Medical Oncology Section, University Hospital P. Giaccone
Palermo, Italy
Giuseppina Novo, MD, PhD
Associate Professor of Cardiology
Biomedic Department of Internal Medicine and Specialities (DIBIMIS) University of Palermo, Italy
Division of Cardiology, University Hospital P. Giaccone
Palermo, Italy
Patrizio Lancellotti, MD, PhD
University of Liège Hospital, GIGA Cardiovascular Sciences
Department of Cardiology
CHU Sart Tilman, Liège, Belgium
Gruppo Villa Maria Care and Research, Anthea Hospital
Bari, Italy
Antonio Giordano, MD PhD
Director, Sbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology
College of Science and Technology
Temple University
PA 19122
USA
Fausto J. Pinto, MD, PhD, FESC, FACC, FSCAI, FASE
Professor, University Hospital Santa Maria, CHLN
University of Lisbon, Portugal
Dept. of Cardiology
Av Prof Egas Moniz
Lisboa 1649-028 Portugal
Content
Introduction.- Mechanisms of Cardiovascular Damage Induced by Traditional Chemotherapy.- Molecular Mechanisms of Cardiovascular Damage Induced by Anti HER2 Therapies.- Cardiovascular Damage Induced by Radiotherapy.- Cardiovascular Damage Induced by Anti-VEGF Therapy.- Cardiovascular Damage Induced by Anti-BCR-ABL TKIs.- Heart Failure and Left Ventricular Dysfunction.- Coronary Artery Disease.- Peripheral Artery Disease and Stroke.- Valvular Heart Disease.- Arterial Hypertension.- Atrial Fibrillation in Cancer.- Management of QT Prolongation Induced by Anti-cancer Drugs.- Pulmonary Hypertension Induced by Anti-cancer Drugs.- Venous Thromboembolism.- Early Detection of Cardiac Damage.- Diagnosis of Cardiac Damage: Role of Stress Echo.- Early Detection and Monitoring of Vascular Damage.- Prevention and Clinical Management of Cardiovascular Damage Induced by Anticancer Drugs: Need for Early Biomarkers and Cardio- and Vasculo-Protection in Personalized Therapy.- Cardiovascular Damage in Clinical Trials.